CompletedPhase 3NCT00418262
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Studying Fetal alcohol syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oklahoma
- Principal Investigator
- Laura J McGuinn, M.D.University of Oklahoma
- Intervention
- Atomoxetine(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 4-11 years · All sexes
- Timeline
- 2005 – 2015
Study locations (1)
- OU Child Study Center, Oklahoma City, Oklahoma, United States
Collaborators
Mark L. Wolraich
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00418262 on ClinicalTrials.govOther trials for Fetal alcohol syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07016009Thrive Person-Centered Planning Program for Young Adults With Fetal Alcohol Spectrum DisordersUniversity of Rochester
- RECRUITINGNANCT05686473Psychoeducation of Parents to Children With FASDSorlandet Hospital HF
- RECRUITINGNANCT06847165Trigeminal Nerve Stimulation for Children With Prenatal Alcohol ExposureUniversity of California, Los Angeles
- ENROLLING BY INVITATIONNANCT06935461Families Moving Forward Bridges: An Early Intervention for Infants and Toddlers With PAE With or At-risk for FASDUniversity of Washington
- RECRUITINGNANCT06638463My Health Coach App RCTUniversity of Rochester
- RECRUITINGNANCT05960461Families Moving Forward (FMF) Connect Pro for Mental Health ProvidersUniversity of Rochester
- RECRUITINGNANCT06005181The Synchrony Study: Examining Music Training for Children With FASDThe Mind Research Network
- RECRUITINGPHASE2NCT04395196RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol ExposureWayne State University